Lexicon Pharma (LXRX) Tops Q4 EPS by 21c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.16 +0.47%
Revenue Growth %: -86.1%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -86.1%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.31), $0.21 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $23 million versus the consensus estimate of $15.64 million.
As of December 31, 2016, Lexicon had $346.5 million in cash and investments, as compared to $395.6 million as of September 30, 2016 and $521.4 million as of December 31, 2015.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Green Dot and CommerceOne shareholders approve acquisition deal
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
